甘精胰島素市場，依類型，依糖尿病類型，依配銷通路，依地理

Insulin Glargine Market, By Type, By Diabetes Type, By Distribution Channel, By Geography

出版日期: 2024年03月20日 | 出版商:

Coherent Market Insights | 英文 167 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2024年全球甘精胰島素市值為54.5億美元，預計到2031年將達84.3億美元，2024年至2031年年複合成長率(CAGR)為6.4%。

報告範圍		報告詳情
基準年：	2023年	2023/2024 年市場規模：	54.5 億美元
歷史數據：	2019年至2023年	預測期：	2024年至2031年
預測期間 2023/2024 至 2030/2031 年複合成長率：	6.40%	2030/2031 價值預測：	84.3 億美元

甘精胰島素市佔率 (%)，依地區，2024 年

甘精胰島素，也稱為來得時，是一種長效基礎胰島素，用於治療糖尿病。它是透過重組 DNA 技術製造的人類胰島素的合成形式，經過改造可溶於酸性環境。注射後，它在皮下組織中沉澱並形成微晶體，形成一個儲存庫，胰島素逐漸被吸收到血液中。這種延長的釋放和作用持續時間允許每日一次給藥，以幫助第 1 型和第 2 型糖尿病患者在 24 小時內控制血糖值。與其他基礎胰島素（例如地特胰島素和 NPH 胰島素）相比，甘精胰島素的吸收速度較慢，因此可以在血液中提供平穩且一致的胰島素水平。

市場動態：

全球甘精胰島素市場的成長是由全球糖尿病盛行率不斷上升所推動的。根據國際糖尿病聯盟2021 的估計，2021 年將有超過5.37 億成年人患有糖尿病，預計到2030 年這一數字將增至6.43 億，到2045 年將增至7.83 億。市場成長，因為糖尿病對糖尿病的影響較大。然而，成本限制，尤其是在發展中國家，是一種限制。從積極的一面來看，持續開發更有效、更方便的藥物輸送技術預計將帶來新的機會。

研究的主要特點：

該報告對全球甘精胰島素市場進行了深入分析，並提供了以2023年為基準年的預測期（2024-2031年）的市場規模（十億美元）和年複合成長率（CAGR%）。
它闡明了不同區隔市場的潛在收入機會，並解釋了該市場有吸引力的投資主張矩陣。
這項研究還提供了有關市場促進因素、限制因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採取的競爭策略的重要見解。
它根據以下參數描述了全球甘精胰島素市場的主要參與者——公司亮點、產品組合、主要亮點、財務表現和策略。
該報告的見解將使行銷人員和公司管理當局能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
全球甘精胰島素市場報告迎合了該行業的各個利益相關者，包括投資者、供應商、產品製造商、分銷商、新進業者和財務分析師。
利害關係人可以透過用於分析全球甘精胰島素市場的各種策略矩陣輕鬆做出決策。

Report Coverage	Report Details
Base Year:	2023	Market Size in 2023/2024:	US$ 5.45 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2023/2024 to 2030/2031 CAGR:	6.40%	2030/2031 Value Projection:	US$ 8.43 Bn

Insulin glargine, also known as Lantus, is a long-acting basal insulin that is used for the treatment of diabetes mellitus. It is a synthetic form of human insulin created through recombinant DNA technology, engineered to be soluble in acidic environments. Upon injection, it precipitates and forms microcrystals in the subcutaneous tissue, creating a depot from which insulin is gradually absorbed into the bloodstream. This extended release and duration of action profile allows once-daily dosing to help control blood glucose levels in patients with type 1 and type 2 diabetes over 24 hours. Insulin glargine has a slower absorption profile as compared to other basal insulins such as insulin detemir and insulin NPH, and thus, provides a smooth and consistent level of insulin in the blood.

Market Dynamics:

Global insulin glargine market growth is driven by growing prevalence of diabetes worldwide. According to estimates by the International Diabetes Federation 2021, over 537 million adults lived with diabetes in 2021, and the number is projected to rise to 643 million by 2030 and 783 million by 2045. Increasing geriatric population also contributes to market growth since diabetes is more common in older age groups. However, cost constraints, especially in developing countries, acts as a restrain. On the positive side, ongoing development of more effective and convenient drug delivery technologies is expected to present new opportunities.

Key Features of the Study:

This report provides in-depth analysis of the global insulin glargine market, and provides market size (USD BN) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global insulin glargine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study includes Sanofi, Biocon, Eli Lilly and Company, Boehringer Ingelheim, Gan & Lee, Kalbe Pharma, Polus Biopharm, Samsung Bioepis, Wockhardt, Novo Nordisk AS, Julphar, and Viatris Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global insulin glargine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global insulin glargine market.

Detailed Segmentation

Type:
- Lantus
- Basaglar
- Toujeo
- Soliqua/Suliqua
- Others
Diabetes Type:
- Type 2 Diabetes
- Type 1 Diabetes
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Company Profiles:
- Sanofi
- Biocon
- Eli Lilly and Company
- Boehringer Ingelheim
- Gan & Lee
- Kalbe Pharma
- Polus Biopharm
- Samsung Bioepis
- Wockhardt
- Novo Nordisk AS
- Julphar
- Viatris Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Diabetes Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Increasing prevalence of diabetes worldwide
- High cost of insulin glargine
- Increase in awareness about diabetes management
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Insulin Glargine Market- Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Insulin Glargine Market, By Type, 2019-2031, (USD BN)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Lantus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Basaglar
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Toujeo
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Soliqua/Suliqua
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

6. Global Insulin Glargine Market, By Diabetes Type, 2019-2031, (USD BN)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Type 2 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Type 1 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

7. Global Insulin Glargine Market, By Distribution Channel, 2019-2031, (USD BN)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

8. Global Insulin Glargine Market, By Region, 2019-2031, (USD BN)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
North America
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
U.K.
Germany
Italy
France
Spain
Russia
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD BN)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Biocon
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Gan & Lee
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Kalbe Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Polus Biopharm
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Samsung Bioepis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Wockhardt
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novo Nordisk AS
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Julphar
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies